Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA5 | P30532 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065433 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1422881 | 0.95 | CHRNB2 (0.90) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1423089 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1422554 | 0.86 | CHRNB2 (0.76) | CHRNB2CHRNA5CHRNA4RAB9ANPC1 | |
| SCHEMBL1423608 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1423100 | 0.85 | CHRNB2 (0.73) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1422802 | 0.83 | CHRNB2 (0.71) | CHRNB2CHRNA5CHRNA4GRM5SMN1; SMN2 | |
| SCHEMBL1422910 | 0.82 | CHRNB2 (0.70) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1423419 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA5CHRNA4GRM5RAB9A | |
| SCHEMBL1422890 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA5CHRNA4RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| EP-3820443-A1 | COMBINATIONS OF POSITIVE ALLOSTERIC MODULATORS AND NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR TREATING OCULAR CONDITIONS | Oyster Point Pharma, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-112638364-A | Combination of positive allosteric modulators and nicotinic acetylcholine receptor agonists for the treatment of ocular disorders | 奥伊斯特普安生物制药公司 | 2021-04-09 | — | — | CN | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | SAINT JOSEPH'S UNIVERSITY | 2019-02-21 | — | — | US | claimed |
| EP-3429563-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | University of the Sciences in Philadelphia (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017160813-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | UNIVERSITY OF THE SCIENCES (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2010138600-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| EP-2255848-A2 | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | NeuroSearch AS (DK) | 2010-12-01 | — | — | EP | claimed |
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | claimed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | claimed |
| EP-1881979-B1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-08-11 | — | — | EP | claimed |
| US-20090312347-A1 | Novel oxadiazole derivatives and their medical use | SANIONA A/S (DK) | 2009-12-17 | — | — | US | claimed |
| CN-101605542-A | Pharmaceutical compositions and methods of use thereof | ABBOTT LAB (US) | 2009-12-16 | — | — | CN | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| EP-1881979-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006114400-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312347-A1 | Novel oxadiazole derivatives and their medical use | CHRNA3, CHRNA5, CHRNB3 | CHRNB2 10/4885CHRNA5 2/4885CHRNA4 5/4885 |
| US-20190054067-A1 | COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE-LIKE BEHAVIOR IN A SUBJECT | CHRNA4, CHRNA5, CHRNE | CHRNB2 9/4885CHRNA5 2/4885CHRNA4 1/4885 |
| US-20100234349-A1 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | CHRNA10, CHRNA4, CHRNA5 | CHRNB2 12/4885CHRNA5 3/4885CHRNA4 2/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA5 3/4885CHRNA4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.